Washington, D.C. 20549







Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): March 29, 2017





(Exact name of registrant as specified in its charter)




Delaware   001-37539   27-4825712

(State or other jurisdiction

of incorporation)



File Number)


(I.R.S. Employer

Identification No.)


400 East Jamie Court, Suite 101

South San Francisco, CA 94080

(Address of principal executive offices, including zip code)


(650) 741-7700

(Registrant’s telephone number, including area code)





Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))







Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.




On March 29, 2017, Michael W. Bonney notified the board of directors (the “Board”) of Global Blood Therapeutics, Inc., a Delaware corporation (the “Company”), that he intends to resign from the Board, including all committees of the Board on which he serves, effective as of the Company’s next annual meeting of stockholders to be held on June 20, 2017 (the “Annual Meeting”), and accordingly, he will not stand for re-election at the Annual Meeting. Mr. Bonney is currently a member of the Compensation Committee of the Board and the Nominating and Corporate Governance Committee of the Board. Mr. Bonney’s decision to resign was not the result of any disagreement with the Company on any matters relating to the Company’s operations, policies or practices.













Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: March 30, 2017       GLOBAL BLOOD THERAPEUTICS, INC.

/s/ Jeffrey Farrow

            Jeffrey Farrow
            Chief Financial Officer
            (Principal Financial Officer)